XTX202 in Patients With Advanced Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

January 18, 2022

Primary Completion Date

March 22, 2025

Study Completion Date

March 25, 2025

Conditions
Advanced Solid Tumor
Interventions
DRUG

XTX202

XTX202 Monotherapy

Trial Locations (15)

15213

UPMC Hillman Cancer Center Pavilion, Pittsburgh

20007

Georgetown University Medical Center, Washington D.C.

28078

Carolina BioOncology Institute, Huntersville

33612

Moffitt Cancer Center, Tampa

37203

Sarah Cannon Research Institute, Nashville

43210

The Ohio State University Wexner Medical Center James Cancer Hospital and Solove Research Institute, Columbus

52242

University of Iowa Hospitals and Clinics, Iowa City

55101

HealthPartners Cancer Center at Regions Hospital, Saint Paul

90033

Norris Comprehensive Cancer Center, Los Angeles

90095

University of California Los Angeles, Los Angeles

92093

UC San Diego Moores Cancer Center, La Jolla

92663

Hoag Memorial Hospital Presbyterian- Newport Beach, Newport Beach

02114

Massachusetts General Hospital, Boston

07960

Atlantic Health System/Morristown Medical Center, Morristown

08903

Rutgers Cancer Institute of NJ, New Brunswick

All Listed Sponsors
lead

Xilio Development, Inc.

INDUSTRY